UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 13.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,716,929 shares of the company's stock after purchasing an additional 206,482 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.35% of Elanco Animal Health worth $20,792,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ELAN. FMR LLC grew its stake in Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after acquiring an additional 37,022,891 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Elanco Animal Health by 6.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock worth $216,774,000 after acquiring an additional 1,074,274 shares in the last quarter. Shapiro Capital Management LLC grew its stake in Elanco Animal Health by 7.5% in the 4th quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company's stock worth $149,640,000 after acquiring an additional 862,900 shares in the last quarter. Magnetar Financial LLC grew its stake in Elanco Animal Health by 13.7% in the 4th quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock worth $145,711,000 after acquiring an additional 1,454,082 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Elanco Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company's stock worth $99,102,000 after acquiring an additional 312,165 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research reports. Barclays lowered their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. UBS Group lowered their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus upped their price target on shares of Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 19th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Elanco Animal Health has an average rating of "Hold" and a consensus price target of $15.17.

Insider Activity at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This represents a 9.86% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.89% of the stock is currently owned by corporate insiders.

Elanco Animal Health Stock Down 0.4%

NYSE:ELAN traded down $0.06 during midday trading on Friday, reaching $13.46. 7,178,699 shares of the stock traded hands, compared to its average volume of 5,116,818. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.80. The business has a 50-day moving average of $10.60 and a two-hundred day moving average of $11.39. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a market capitalization of $6.68 billion, a PE ratio of 33.65, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. During the same quarter in the prior year, the company posted $0.34 earnings per share. Elanco Animal Health's revenue for the quarter was down 1.0% compared to the same quarter last year. On average, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.